You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海醫藥(02607.HK)子公司新型抑酸劑X842項目上市許可申請獲內地受理
阿思達克 02-20 17:02
上海醫藥(02607.HK)公布,全資子公司上藥信誼合作開發的新型抑酸劑X842項目的上市許可申請,正式獲得國家藥品監督管理局受理。 公司指,X842是新一代鉀離子競爭性酸阻斷劑(P-CAB)口服藥物,現有數據顯示具有起效迅速、抑酸作用強且持久、不良反應少等優點。公司於2021年10月與貴州生諾生物科技及其全資子公司江蘇太瑞生諾簽訂《合作協議》,獲得X842項目原料藥及製劑在中國區域的獨家委託生產和所有適應症的工業銷售權。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account